Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trialDaniel S. Reich, Sibyl Wray, Sergii Moskovko et al.|The Lancet Neurology|2021Cited by 192
Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trialDiego Cadavid, Rogier Hintzen, Abdullatif Al Khedr et al.|The Lancet Neurology|2019Cited by 185
Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trialBruce Cree, Piotr Sokolowski, Richard Macdonell et al.|The Lancet Neurology|2020Cited by 104
Predictors of treatment switching in the Big Multiple Sclerosis Data NetworkTim Spelman, Tobias Sejbæk, Koen de Gans et al.|Frontiers in Neurology|2023Cited by 9